XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.26.1

Organization and Basis of Presentation (Details) |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 15 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 20, 2026 | Apr. 17, 2026 USD ($) | Apr. 15, 2026 USD ($) | Nov. 07, 2025 USD ($) | Mar. 09, 2025 USD ($) shares | Apr. 30, 2026 USD ($) | Mar. 31, 2026 USD ($) clinic | Mar. 31, 2025 USD ($) | Mar. 31, 2026 USD ($) clinic | Dec. 31, 2025 USD ($) | Dec. 31, 2024 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of late stage clinical programs | clinic |  |  |  |  |  |  | 4 |  | 4 |  |
Number of GMP-Licensed |  |  |  |  |  |  | 2 |  | 2 |  |
Minimum development period of proprietary manufacturing platform |  |  |  |  |  |  | 9 years |  |  |  |
Minimum number of distinct viral vectors utilized |  |  |  |  |  |  | 20 |  | 20 |  |
Future contingent consideration |  |  |  |  |  |  | $ 920,000 | $ 615,000 |  |  |
Accumulated deficit |  |  |  |  |  |  | 862,536,000 |  | $ 862,536,000 | $ 816,223,000 |
Cash flows from operations |  |  |  |  |  |  | 17,810,000 | (36,828,000) |  |  |
Cash, cash equivalents |  |  |  |  |  |  | 73,758,000 | 68,610,000 | 73,758,000 | 68,193,000 | $ 105,668,000
Proceeds from the issuance of ordinary shares |  |  |  |  |  |  | 14,027,000 | $ 4,482,000 |  |  |
Outstanding debt obligation |  |  |  |  |  |  | 24,866,000 |  | 24,866,000 | $ 24,648,000 |
Perceptive Credit Holdings | Secured Debt |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Outstanding debt obligation |  |  |  |  |  |  | 25,000,000 |  | 25,000,000 |  |
Hologen Strategic Agreement | Hologen Limited |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone funding upfront payment received |  |  |  |  | $ 200,000,000 |  |  |  | 105,000,000 |  |
Hologen Limited | Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Class A shares of Hologen received in transaction | shares |  |  |  |  | 500,000 |  |  |  |  |  |
Hologen Limited | Hologen Strategic Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone funding upfront payment received |  |  |  |  |  |  |  |  | 105,000,000 |  |
Additional funding payment received |  |  |  |  |  |  | 105,000,000 |  |  |  |
Milestone payment to be received |  |  |  |  |  |  | $ 95,000,000 |  | $ 95,000,000 |  |
Eli Lilly | Eli Lilly Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Initial funding |  |  |  | $ 75,000,000 |  |  |  |  |  |  |
Contingent funding available |  |  |  | 400,000,000 |  |  |  |  |  |  |
Milestone funding contingent on development and regulatory approval |  |  |  | $ 135,000,000 |  |  |  |  |  |  |
Maximum | Hologen Strategic Agreement | Hologen Limited |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone funding to provide additional capital |  |  |  |  | $ 230,000,000 |  |  |  |  |  |
Subsequent Event | Public Offering |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Proceeds from the issuance of ordinary shares |  | $ 100,000,000 |  |  |  |  |  |  |  |  |
Net proceeds from issuance of common stock, net |  | $ 93,300,000 |  |  |  |  |  |  |  |  |
Subsequent Event | Research, Development And Other Assets |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Upfront cash payment |  |  | $ 25,000,000 |  |  |  |  |  |  |  |
Future contingent consideration |  |  | 50,000,000 |  |  |  |  |  |  |  |
Sales threshold payment |  |  | $ 250,000,000 |  |  |  |  |  |  |  |
Subsequent Event | Hologen Neuro AI Limited | MeiraGTx Neuro UK Limited |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of issued share capital | 30.00% |  |  |  |  |  |  |  |  |  |
Subsequent Event | Hologen Neuro AI Limited | Hologen Limited |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Minority interest ownership percentage | 70.00% |  |  |  |  |  |  |  |  |  |
Subsequent Event | MeiraGTx Manufacturing Limited | JJDC |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of business days |  |  | 5 days |  |  |  |  |  |  |  |
Subsequent Event | MeiraGTx Manufacturing Limited | Hologen Limited |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Maximum ownership percentage | 40.00% |  |  |  |  |  |  |  |  |  |
Agreement, Option exercise period | 3 years |  |  |  |  |  |  |  |  |  |
Subsequent Event | Asset Purchase Agreement | JJDC |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Ownership interest |  |  | 5.00% |  |  |  |  |  |  |  |
Subsequent Event | Hologen Limited | Hologen Strategic Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone funding upfront payment received |  |  |  |  |  | $ 105,000,000 |  |  |  |  |

X
- Definition Additional milestone funding received in collaboration with Hologen Limited. + References No definition available. + Details
Name: | mgtx_AdditionalMilestonePaymentReceived
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the option exercise period. + References No definition available. + Details
Name: | mgtx_AgreementOptionExercisePeriod
Namespace Prefix: | mgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period over which grantee's right to purchase shares under transaction arrangement is no longer effective, and the company's irrevocable option to repurchase shares becomes effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + References No definition available. + Details
Name: | mgtx_AgreementSellOrTransferOfSharesNoticePeriod
Namespace Prefix: | mgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock issued during period in connection with strategic agreement. + References No definition available. + Details
Name: | mgtx_ClassSharesOfHologenReceivedInTransaction
Namespace Prefix: | mgtx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Funding received from the Company's collaboration agreement with Janssen Pharmaceuticals for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases.. + References No definition available. + Details
Name: | mgtx_CollaborationAgreementFundingReceived
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals. + References No definition available. + Details
Name: | mgtx_ContingentFundingAvailable
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the maximum ownership percentage may hold if option is exercised. + References No definition available. + Details
Name: | mgtx_MaximumOwnershipPercentageMayHoldIfOptionIsExercised
Namespace Prefix: | mgtx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone funding available in other near-term cash consideration upon the achievement of certain development and regulatory approval milestones. + References No definition available. + Details
Name: | mgtx_MilestoneFundingAvailableUponCertainDevelopmentAndRegulatoryApprovals
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received as additional capital of up to fund the development of the Clinical Programs and the Delivery Device + References No definition available. + Details
Name: | mgtx_MilestoneFundingToProvideAdditionalCapital
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone funding received in collaboration with Hologen Limited. + References No definition available. + Details
Name: | mgtx_MilestoneFundingUpfrontPaymentReceived
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment to be received. + References No definition available. + Details
Name: | mgtx_MilestonePaymentToBeReceived
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the minimum duration over which the company has developed its proprietary manufacturing platform process. + References No definition available. + Details
Name: | mgtx_MinimumDevelopmentPeriodOfProprietaryManufacturingPlatform
Namespace Prefix: | mgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the minimum number of different viral vectors developed and tested, demonstrating leading yield, quality, and commercial readiness. + References No definition available. + Details
Name: | mgtx_MinimumNumberOfDistinctViralVectorsUtilized
Namespace Prefix: | mgtx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Net Proceeds From Issuance Of Common Stock + References No definition available. + Details
Name: | mgtx_NetProceedsFromIssuanceOfCommonStock
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the total number of manufacturing facilities licensed for Good Manufacturing Practice (GMP) production. + References No definition available. + Details
Name: | mgtx_NumberOfGmpLicensedManufacturingFacilities
Namespace Prefix: | mgtx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the total number of clinical programs that have reached late-stage development. + References No definition available. + Details
Name: | mgtx_NumberOfLateStageClinicalPrograms
Namespace Prefix: | mgtx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of sales threshold required to trigger contingent consideration payment. + References No definition available. + Details
Name: | mgtx_SalesThresholdRequiredToTriggerContingentConsiderationPayment
Namespace Prefix: | mgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details
Name: | us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-1 + Details
Name: | us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_NetCashProvidedByUsedInOperatingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_NotesPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of accumulated undistributed earnings (deficit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_LineOfCreditFacilityAxis=mgtx_PerceptiveCreditHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgtx_HologenTransactionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mgtx_HologenLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mgtx_HologenLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mgtx_EliLillyAndCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgtx_EliLillyAndCompanyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=mgtx_PublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=mgtx_ResearchDevelopmentAndOtherAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=mgtx_HologenNeuroAiLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mgtx_MeiragtxNeuroUkLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=mgtx_MeiragtxManufacturingLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JohnsonAndJohnsonInnovationJjdcIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |